Eli Lilly (LLY) Stock: Ken Griffin Quadruples Stake as Foundayo Launches in UK
TLDR
- Ken Griffin’s Citadel nearly quadrupled its LLY position in Q2, buying 704,000 additional shares
- Citadel now holds 945,000 LLY shares worth $1.18 billion, making it the fund’s sixth-largest position
- LLY stock is up 17% year-to-date and recently hit an all-time high
- Eli Lilly launched its oral weight-loss pill Foundayo in the UK, the first European country to carry it
- LLY carries a consensus Strong Buy rating with an average price target of $1,375.78
Eli Lilly’s stock is trading around $1,228, up 17% on the year, after Ken Griffin’s Citadel nearly quadrupled its position in the pharmaceutical company during the second quarter of 2026.
Citadel purchased 704,000 additional LLY shares in Q2, bringing its total holding to 945,000 shares valued at $1.18 billion. That makes Eli Lilly Citadel’s sixth-largest position across nearly 7,500 stock holdings.
Citadel appears to have bought into a dip. LLY was down 21% year-to-date through the end of April before recovering. Griffin’s firm loaded up throughout Q2, and the stock has climbed sharply since.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
